Abstract: The present invention provides methods of identifying biomarkers indicative of the presence of a neurodevelopmental disorder, including an autism spectrum disorder, in an individual, using cytometry and mass spectrometry. The invention further provides methods of using the identified biomarkers to diagnose the presence of a neurodevelopmental disorder, including an autism spectrum disorder.
Type:
Grant
Filed:
May 5, 2006
Date of Patent:
October 20, 2009
Assignee:
The Regents of the University of California
Abstract: Methods are disclosed for designing an antibody reagent for use in an assay for the detection of an analyte to obtain an optimum assay sensitivity and/or dynamic range. The antibody reagent is a conjugate of a small molecule attached by a spacer group to an antibody for the analyte. The method comprises controlling, in the preparation of the conjugate, reaction parameters comprising the hydrophobicity or hydrophilicity of the spacer group, the length of the spacer group, the number of molecules of the small molecule attached to the antibody and the point of attachment of the small molecule to the antibody to obtain an optimum assay sensitivity and/or dynamic range.
Type:
Application
Filed:
April 15, 2008
Publication date:
October 15, 2009
Applicant:
SIEMENS HEALTHCARE DIAGNOSTICS INC., A CORPORATION OF CALIFORNIA
Inventors:
Sandra A. Lewisch, Pratap Singh, Viral Desai, Karen L. Krakowski, James E. Duffy
Abstract: The invention discloses nearly 474 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Kinase, Adaptor/Scaffold proteins, Phosphatase, G protein Regulator/Guanine Nucleotide Exchange Factors/GTPase Activating Proteins, Cytoskeleton Proteins, DNA Binding Proteins, Phospholipase, Receptor Proteins, Enzymes, DNA Repair/Replication Proteins, Adhesion Proteins, and Proteases, as well as other protein types.
Type:
Application
Filed:
February 29, 2008
Publication date:
October 15, 2009
Inventors:
Roberto Polakiewicz, Ailan Guo, Albrecht Moritz, Klarisa Rikova, Kimberly Lee, Erik Spek, Yu Li, Charles Farnsworth
Abstract: The invention provides a simple method for diagnosing a non-symptomatic or symptomatic human or animal with transmissible spongiform encephalopathy.
Type:
Grant
Filed:
July 28, 2006
Date of Patent:
October 13, 2009
Assignee:
IDEXX Laboratories, Inc.
Inventors:
Roy Jackman, Linda Ann Terry, Sally Jane Everest
Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis.
Type:
Application
Filed:
April 17, 2008
Publication date:
September 24, 2009
Inventors:
Sarah C. Bodary-Winter, Hilary Clark, Janet K. Jackman, Jill R. Schoenfeld, P. Mickey Williams, William I. Wood, Thomas D. Wu
Abstract: Compositions and assay methods for and relating to the detection of glycated hemoglobin are provided. In particular, the presence and level of glycated hemoglobin can be detected in a blood sample. The compositions comprise microparticles which have zinc coating for use in the improved binding of proteins exhibiting a zinc binding domain, in particular glycated hemoglobin.
Abstract: A method to determine specificity of ligand binding includes comparing a solid phase carrier first extract obtained by pre-treating a sample with a ligand-immobilized solid phase carrier and a solid phase carrier second extract obtained by treating the pretreated sample again with a ligand-immobilized solid phase carrier in terms of the proteins contained therein, and identifying a protein whose content is remarkably decreased in the second extract compared to the first extract, in order to solve 1) the problem of the solubility of subject ligand, 2) the problem of the non-specific protein-denaturing effect of the subject ligand added, and the like, in antagonism experiments in target search using an affinity resin.
Type:
Grant
Filed:
October 15, 2004
Date of Patent:
September 22, 2009
Assignee:
Reverse Proteomics Research Institute Co., Ltd.
Abstract: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.
Type:
Application
Filed:
March 4, 2009
Publication date:
September 17, 2009
Applicant:
ABBOTT LABORATORIES
Inventors:
Larry G. Birkenmeyer, Anthony S. Muerhoff, Suresh M. Desai, George J. Dawson, Bruce J. Dille
Abstract: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.
Type:
Application
Filed:
January 23, 2007
Publication date:
September 10, 2009
Inventors:
Viktor Roschke, Craig A. Rosen, Steven M. Ruben
Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.
Type:
Application
Filed:
May 25, 2006
Publication date:
September 10, 2009
Applicant:
The Johns Hopkins University
Inventors:
Jinong Li, Saraswati Sukumar, Daniel W. Chan
Abstract: An in vitro method for detecting the presence in a body sample of auto-antibodies for the PDGF receptor suitable for the diagnosis and prognosis of autoimmune diseases, in particular the systemic sclero-is and related diagnostic kits. Use of an inhibitor of ROS and/or Ras-ERK1/2 for the preparation of a medicament for therapeutic treatment of autoimmune diseases or of treating the Graft-Versus-Host-Reaction (GVHR). Pharmaceutical composition comprising an effective amount of an inhibitor of ROS and/or Ras-ERK1/2, and proper diluents, and/or excipients, and/or adjuvants.
Abstract: Isolated polynucleotides encoding novel galectin-8 variants polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating rheumatoid arthritis (RA) and other joint/chronic inflammatory diseases.
Type:
Application
Filed:
May 9, 2006
Publication date:
September 3, 2009
Applicants:
Yissum Research Development Co. of the Hebrew University of Jersalem, Medical Research Fund of Tel Aviv Sourasky Medical Center
Abstract: The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.
Type:
Application
Filed:
February 29, 2008
Publication date:
September 3, 2009
Inventors:
Roberto Polakiewicz, Valerie Goss, Albrecht Moritz, Ting-Lei Gu, Kimberly Lee
Abstract: The invention relates to methods for detecting and identifying potential biomarkers of high-grade cervical dysplasia in an individual human subject. The invention also relates to newly discovered biomarkers, as set forth in Tables 1-4 herein, which are associated with the dysplastic state of cervical cells. It has been discovered that a differential level of expression of any of these markers or combination of these markers correlates with a dysplastic condition in a human subject, e.g., a patient.
Type:
Application
Filed:
March 12, 2007
Publication date:
September 3, 2009
Applicants:
CYTYC CORPORATION, NORTHEASTERN UNIVERSITY
Inventors:
Shiaw-Lin Wu, William S. Hancock, Barry L. Karger, James Linder, David W. Hanlon
Abstract: The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as “Bim”, and to genetic sequences encoding same. The molecules of the present invention are useful, for example, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
Type:
Grant
Filed:
April 24, 2006
Date of Patent:
September 1, 2009
Assignee:
The Walter and Eliza Hall Institute of Medical Research
Inventors:
Suzanne Cory, Jerry Adams, David C. S. Huang, Liam O'Connor, Andreas Strasser, Hamsa Puthalakath, Lorraine O'Reilly
Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the CACNA1E gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the CACNA1E gene.
Type:
Application
Filed:
April 7, 2006
Publication date:
August 27, 2009
Inventors:
Guoying Yu, Edward Moler, Michael Rowe, Christin Tse, Xie Xu
Abstract: The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.
Abstract: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.
Abstract: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.
Type:
Application
Filed:
April 12, 2006
Publication date:
August 20, 2009
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
Abstract: This invention relates to methods of diagnosing dilated cardiomyopathy using analysis of the lamin A protein and sumylation of same, as well as methods for treating dilated cardiomyopathy, comprising enhancing the sumoylation of the lamin A protein in a subject in need thereof.
Type:
Application
Filed:
January 22, 2009
Publication date:
August 13, 2009
Applicant:
University of Kentucky Research Foundation
Abstract: The invention discloses 99 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Brain Ischemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor/scaffold proteins, adhesion proteins, G proteins/GTPase/Guanine nucleotide exchange factors, Calcium binding proteins, cytoskeletal proteins, Channel proteins, Chaperone proteins, Helicases, Motor proteins, Translation proteins, RNA binding proteins, Ubiquitin conjugating system proteins, vesicle proteins and Receptor proteins.
Type:
Application
Filed:
May 11, 2007
Publication date:
August 13, 2009
Inventors:
Ailan Guo, Roberto Polakiewicz, Kimberly Lee
Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.
Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.
Type:
Application
Filed:
October 28, 2008
Publication date:
July 30, 2009
Applicants:
The Governing Council of the University of Toronto, HSC Research and Development Limited Partnership
Inventors:
Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
Abstract: Hypoxia, a state of lower than normal tissue oxygen tension, has recently been implicated in a host of human diseases, including cancer, heart disease, and neurological disorders. Novel associations between p97 and other proteins, including UBX-domain-containing proteins (UBX-polypeptides), HIF1?, and a variety of E3 ligases are provided herein. The disclosure provides complexes comprising UBX-domain-containing polypeptides (UBX-polypeptides) and other polypeptides involved in the degradation of ubiquitinated proteins. In addition, the disclosure provides uses for active agents that modulate protein-protein complex formation between an UBX-polypeptide and its complementary-binding substrate. For example, the disclosure provides methods for treating or preventing hypoxia-related disorders or conditions in a patient or a cell by administration of an active agent that modulates the activity of an UBX-polypeptide and/or its complementary binding-substrate.
Type:
Application
Filed:
November 5, 2008
Publication date:
July 30, 2009
Applicant:
California Institute of Technology
Inventors:
Gabriela Alexandru, Raymond Deshaies, Johannes Graumann
Abstract: Disclosed are biological markers for obesity and methods for diagnosing and treating obesity and related conditions by detecting and modulating the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor. Also disclosed are methods for discovering new therapeutics which modulate the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor, in particular which prevent the binding of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor.
Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein ASC in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of breast cancer.
Type:
Grant
Filed:
April 14, 2006
Date of Patent:
July 28, 2009
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
Abstract: A type IV collagen-like immunoreactive peptide and an antibody thereof which are useful for detecting nephritis, a method for selecting a type IV collagen-like immunoreactive peptide, a method for screening an immunoreactive antibody and an immunoreactive peptide, a nephritis model, a method for detecting chronic nephritis, a vaccine, and a therapeutic agent for nephritis are provided. A type IV collagen-like immunoreactive peptide immunologically reacts with an isolated, chronic nephritis-derived biological sample. Preferably, the type IV collagen-like immunoreactive peptide includes at least one member selected from the group consisting of at least one chain selected from alpha 1 to alpha 6 chains as a constituent alpha chain, at least one region selected from 7S, the central helical domain, and NC1 as a constituent region, and a peptide having 3 to 35 amino acids as a constituent peptide.
Abstract: The present invention relates to a method for identifying a compound capable of modulating the activity of the JAK/STAT pathway and to the use of different JAK/STAT pathway components as a target for the modulation of the activity of the JAK/STAT pathway. Moreover, the present invention is concerned with a method for modulating the activity of the JAK/STAT pathway. Furthermore, the present invention pertains to a pharmaceutical composition and to the use of different JAK/STAT pathway components and/or effector molecules thereof for the manufacture of such composition for the diagnosis, prevention or treatment of a JAK/STAT pathway associated disorder.
Type:
Application
Filed:
June 14, 2006
Publication date:
July 23, 2009
Inventors:
Michael Boutros, Martin Zeidler, Patrick Mueller
Abstract: Methods for enhancement in accuracy of immunochemical analysis of heterogeneous biological fluids containing exogenous substances that can interfere in immunochemical analysis for endogenous analytes of interest. According to this method a heterogeneous biological fluid sample is pretreated with an interferant suppression effective amount of a molybdenum coordination complex, so as to reduce manifestation of the presence of said exogenous material under immunoassay conditions. This invention is suitable for the suppression of manifestation of exogenous substances, specifically metabolites of drugs of abuse, during the immunoassay of biological fluids of infants for detection of endogenous substances indicative of a wellness or disease state. This invention also has application for similar suppression exogenous substances in the biological fluid of adults that have been inadvertently exposed to such substances (e.g. secondhand smoke).
Abstract: The present invention relates to a method for analysing a cell sample for cell surface-bound or intracellularly bound analytes by providing an array of immobilised specific binding agents for a set of different ligands, where each ligand is specific to a respective cell surface-bound or intracellularly bound analyte, and using the array and the set of ligands in an inhibition type or a direct type assay format to determine cell surface-bound or intracellularly bound analytes in the cell sample. The invention also relates to assay kits for cell characterization.
Type:
Grant
Filed:
March 31, 2004
Date of Patent:
July 21, 2009
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Robert Karlsson, Pascale Richalet-Secordel
Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.
Type:
Application
Filed:
September 29, 2006
Publication date:
July 16, 2009
Applicant:
Genentech, Inc.
Inventors:
Daryl T. Baldwin, Sarah C. Bodary, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood
Abstract: Methods and kits are provided for the simultaneous detection of multiple analytes, i.e. to the determination of whether one or more of a plurality of analytes is present in a sample, particularly the plurality of analytes are structurally unrelated or significantly different, particularly to whether one or more of such analytes is present in a sample in a concentration that is above a predetermined minimum or cutoff value, and particularly for such analytes with different cutoffs. The methods and kits are particularly useful for-screening for the presence of a plurality of drugs (licit and/or illicit), performance-enhancing substances, and other chemicals, and involve a competitive enzyme immunoassay employing one or more conjugates of G6PDH with a plurality of the analytes.
Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
Abstract: The invention generally relates to the field of immunoassays. In particular, the invention relates to use of a calibrator material to calibrate immunoassays for autoantibodies.
Type:
Application
Filed:
December 23, 2008
Publication date:
July 9, 2009
Applicant:
Onclmmune Limited
Inventors:
John F. R. Robertson, Andrea Murray, Caroline Chapman, Anthony Barnes
Abstract: The invention relates to a crystal complex formed by the extracellular domain of EGF receptor (EGFR) and the Fab fragment of anti-EGFR antibody matuzumab (EMD 72000). Especially the invention relates to the identification of the epitope regions on said EGFR, which the antibody matuzumab recognizes as antigen an to which it specifically binds. The invention relates furthermore to protein, peptide and antibody structures which mimic the binding of matuzumab to its epitope region on EGFR, and may be used therefore, as EGFR antagonists with similar or improved properties as compared to matuzumab.
Type:
Application
Filed:
October 2, 2008
Publication date:
July 9, 2009
Applicants:
Merck Patent GmbH, The Trustees of the University of Pennsylvania
Inventors:
Kathryn M. Ferguson, Thorsten Knoechel, Judith Schmiedel
Abstract: A method for detecting presence or absence of a tumor in a mammal and/or its sensitivity to chemotherapies, including, on a biological sample from said mammal, detecting and/or quantifying: presence of an eEF1A1 protein, and/or presence of antibodies directed against an eEF1A1 protein or a fragment including at least one epitope of eEF1a1 protein, and/or presence of a MARK3 protein, and/or presence of antibodies directed against a MARK3 protein or a fragment comprising at least one epitope of the MARK3 protein.
Type:
Application
Filed:
November 27, 2006
Publication date:
July 9, 2009
Applicant:
Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: Compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the invention relates to the use of novel combinations of reagents to provide improved assay performance.
Type:
Application
Filed:
February 10, 2009
Publication date:
July 2, 2009
Applicant:
MESO SCALE TECHNOLOGIES, LLC.
Inventors:
Michael Tsionsky, Eli N. Glezer, Selen Altunata, George Sigal, Jonathan K. Leland, Mark A. Billadeau, Svetlana Leytner, Mark Martin, Larry Helms
Abstract: The invention relates to polypeptides reacting with rheumatism-associated autoantibodies. The invention moreover relates to a diagnostic agent comprising any of said polypeptides, to a diagnostic kit comprising said diagnostic agent and to a process for in vitro detection of rheumatic diseases. The invention furthermore relates to a medicament comprising any of said polypeptides and to the use of said polypeptides for preparing a medicament for the prophylaxis and/or treatment of rheumatic diseases.
Abstract: The invention relates to a method and a device for detecting very small quantities of particles. The inventive method is based on a detection of antigen-antibody reaction products and provides a very high detection sensitivity all the way to the femtomolar or attomolar range.
Abstract: An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.
Type:
Grant
Filed:
July 24, 2006
Date of Patent:
June 16, 2009
Assignee:
B.R.A.H.M.S. Aktiengesellschaft
Inventors:
Andreas Bergmann, Andrea Ernst, Harald Hampel
Abstract: The present invention provides compositions and methods useful for diagnosing cancer and for monitoring the progression and treatment of cancer, as well as targets for treating cancer. The invention provides sperm and testis associated antigens, such as the protein CABYR, as biomarkers and as targets for chemotherapy.
Type:
Application
Filed:
November 26, 2008
Publication date:
May 28, 2009
Inventors:
John C. HERR, Arabinda MANDAL, Henry F. FRIERSON, Jr.
Abstract: The present invention relates to methods and compositions for the normalization of complex analyte mixtures. The invention allows the preparation of profiled samples from highly complex analyte mixtures, allowing the identification of relevant targets or biomarkers. The invention also relates to methods for producing devices, such as a support, suitable for normalization of complex analyte samples. The invention can be used for the normalization of any complex mixture, such as immunogenic libraries, particularly of human source, and to identify or produce biomarkers highly relevant to human traits or conditions.
Type:
Application
Filed:
July 27, 2006
Publication date:
May 28, 2009
Applicant:
BIOSYSTEMS INTERNATIONAL SAS
Inventors:
Laszlo Takacs, Andras Guttman, Mariana Kuras
Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
Type:
Application
Filed:
April 19, 2005
Publication date:
May 21, 2009
Applicant:
PROSCAN RX PHARMA
Inventors:
Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett
Abstract: The present invention provides MSCRAMM® proteins from S. aureus which are putative highly-expressed antigens from methicillin-resistant S. aureus, including communit-associated MRSA (CA-MRSA), and these antigens can thus be utilized in methods of generating antibodies capable of binding these antigens which can be useful in methods of treating or preventing infection from MRSA. The present invention is directed to these proteins, antibodies capable of binding these proteins, methods of generating said antibodies, nucleic acids coding for said proteins, and pharmaceutical compositions or vaccines which include the proteins or antibodies of the present invention in combination with a pharmaceutically acceptable vehicle, carrier or excipient.
Type:
Application
Filed:
February 22, 2007
Publication date:
May 21, 2009
Inventors:
Magnus Hook, Maria Labandeira-Rey, Gabriela M. Bowden
Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
Type:
Application
Filed:
September 11, 2008
Publication date:
May 21, 2009
Inventors:
Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
Abstract: The present invention is related to an in vitro diagnostic assay of enteroviruses, based on the revealing of an immunologic reaction of antigen-antibody recognition type, using antigens or epitopes thereof that do not induce antiviral neutralising antibodies but induce “facilitating” antibodies which increase the viral infection.
Type:
Grant
Filed:
February 9, 2004
Date of Patent:
May 19, 2009
Assignees:
Universite de Lille 2 Droit Et Sante, Centre Hospitalier Regional Universitaire de Lille (Chru de Lille)
Inventors:
Wassim Chehadeh, Didier Hober, Ahmed Bouzidi
Abstract: Compositions for the treatment of neurodegenerative diseases are disclosed. Methods of treating and monitoring progression of a neurodegenerative disease are disclosed. According to the present invention, a selective CB2 receptor modulator may be administered to a mammal for the treatment of a neurodegenerative disease.
Type:
Application
Filed:
October 5, 2007
Publication date:
May 14, 2009
Applicant:
Board of Trustees of the University of Arkansas
Abstract: The present invention relates to a monoclonal antibody selectively recognizing a human platelet alloantigen, a method for detecting the presence or absence of at least one human platelet alloantigen using said antibody, a method for the production of said antibody, a pharmaceutical composition comprising said antibody, and a kit containing said antibody.
Type:
Application
Filed:
June 13, 2008
Publication date:
May 7, 2009
Applicant:
Stiftung fur Diagnostische
Inventors:
Dominique Rigal, Jean Jacques Pin, Yves Merieux
Abstract: The present disclosure provides for method of treatment and/or prevention of disease states that require cystine for maintenance or progression of the disease state. In addition, methods for screening and identifying novel therapeutic agents useful in the treatment of such disease states are described. In one embodiment, the disease state is a cancer, such as, but not limited to, glioma. In this embodiment, methods for the treatment and prevention of glioma by inhibiting cystine uptake or decreasing intracellular cystine concentrations are provided. The present disclosure teaches that glioma cells are dependent on system Xc for cystine uptake. Pharmacological inhibition of system Xc causes a rapid depletion of intracellular glutathione, resulting in decreased cell growth. In contrast, non-malignant astrocytes and cortical neurons remain viable in the presence of Xc inhibitors and continue to take up cystine via alternate amino acid transporters.